Cited by

• The Association between Sleep Duration and Non-Alcoholic Fatty Liver Disease among Japanese Men and Women.

  Imaizumi H, Takahashi A, Tanji N, Abe K, Sato Y, Anzai Y, Watanabe H, Ohira H. Imaizumi H, et al. Obes Facts. 2015;8(4):234-42. doi: 10.1159/000436997. Epub 2015 Jul 1. Obes Facts. 2015. PMID: 26138724 Free PMC article.
• Prevalence of diabetes and incidence of angiopathy in patients with chronic viral liver disease.

  Kuriyama S, Miwa Y, Fukushima H, Nakamura H, Toda K, Shiraki M, Nagaki M, Yamamoto M, Tomita E, Moriwaki H. Kuriyama S, et al. J Clin Biochem Nutr. 2007 Mar;40(2):116-22. doi: 10.3164/jcbn.40.116. J Clin Biochem Nutr. 2007. PMID: 18188413 Free PMC article.
• Letter from South Australia: Afflictions and admonitions.

  Rhodes P. Rhodes P. Br Med J. 1975 Nov 8;4(5992):340-1. doi: 10.1136/bmj.4.5992.340. Br Med J. 1975. PMID: 1238142 Free PMC article. No abstract available.
• Differences in characteristics of glucose intolerance between patients with NAFLD and chronic hepatitis C as determined by CGMS.

  Ochi T, Kawaguchi T, Nakahara T, Ono M, Noguchi S, Koshiyama Y, Munekage K, Murakami E, Hiramatsu A, Ogasawara M, Hirose A, Mizuta H, Masuda K, Okamoto N, Suganuma N, Chayama K, Yamaguchi M, Torimura T, Saibara T. Ochi T, et al. Sci Rep. 2017 Aug 31;7(1):10146. doi: 10.1038/s41598-017-09256-4. Sci Rep. 2017. PMID: 28860506 Free PMC article.
• Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH.

  Kimura Y, Hyogo H, Yamagishi S, Takeuchi M, Ishitobi T, Nabeshima Y, Arihiro K, Chayama K. Kimura Y, et al. J Gastroenterol. 2010 Jul;45(7):750-7. doi: 10.1007/s00535-010-0203-y. Epub 2010 Jan 30. J Gastroenterol. 2010. PMID: 20112031 Clinical Trial.